It is difficult to predict how antibodies will behave when mixed together, even after each has been independently characterized. Here, we present a statistical mechanical model for the activity of antibody mixtures that accounts for whether pairs of antibodies bind to distinct or overlapping epitopes. This model requires measuring n individual antibodies and their n(n−1) 2 pairwise interactions to predict the 2 n potential combinations. We apply this model to epidermal growth factor receptor (EGFR) antibodies and find that the activity of antibody mixtures can be predicted without positing synergy at the molecular level. In addition, we demonstrate how the model can be used in reverse, where straightforward experiments measuring the activity of antibody mixtures can be used to infer the molecular interactions between antibodies. Lastly, we generalize this model to analyze engineered multidomain antibodies, where components of different antibodies are tethered together to form novel amalgams, and characterize how well it predicts recently designed influenza antibodies.
presence of an arbitrary mixture. 21 To test the predictive power of our framework, we apply it to a beautiful recent case 22 study of inhibitory antibodies against the epidermal growth factor receptor (EGFR), 23 where 10 antibodies were individually characterized for their ability to inhibit receptor 24 activity and then all possible 2-Ab and 3-Ab mixtures were similarly tested [6] . We 25 demonstrate that our framework can accurately predict the activity of these mixtures 26 based solely on the behaviors of the ten monoclonal antibody as well as their epitope 27 mappings. 28 Lastly, we generalize our model to predict the potency of engineered multidomain 29 antibodies from their individual components. Specifically, we consider the recent work 30 by Laursen et al. where four single-domain antibodies were assayed for their ability to 31 neutralize a panel of influenza strains, and then the potency of constructs comprising 32 2-4 of these single-domain antibodies were measured [7] . Our generalized model can 33 once again predict the efficacy of the multidomain constructs based upon their 34 constitutive components, once a single fit parameter is inferred to quantify the effects of 35 the linker joining the single-domain antibodies. This enables us to quantitatively 36 ascertain how tethering antibodies enhances the two key features of potency and 37 breadth that are instrumental for designing novel anti-viral therapeutics. Notably, our 38 models do not posit complex molecular synergy between antibodies. Our results 39 therefore show that many antibody mixtures function without synergy, and hence that 40 their effects can be computationally predicted to expedite future experiments. 41 
Results

42
Modeling the mechanisms of action for antibody mixtures 43 Consider a monoclonal antibody that binds to a receptor and inhibits its activity. Two 44 parameters characterize this inhibition: (1) the dissociation constant K D quantifies an 45 antibody's binding affinity (with a smaller value indicating tighter binding) and (2) the 46 potency α relates the activity when an antibody is bound to the activity in the absence 47 of antibody. A value of α = 1 represents an impotent antibody that does not affect 48 activity while α = 0 implies that an antibody fully inhibits activity upon binding. As 49 derived in S1 Text Section A, for an antibody that binds to a single site on a receptor, 50 the activity at a concentration c of antibody is given by
(1)
To characterize a mixture of two antibodies, we not only need their individual dissociation constants and potencies but also require a model for how these antibodies 53 interact. When two antibodies bind to distinct epitopes, the simplest scenario is that 54 their ability to bind and inhibit activity is independent of the presence of the other 55 antibody, and hence that their combined potency when simultaneously bound equals 56 the product of their individual potencies ( Fig 1A) . Alternatively, if the two antibodies 57 compete for the same epitope, they cannot both be simultaneously bound ( Fig 1B) . 58 We also define the general case of a synergistic interaction where the binding of the 59 first antibody alters the binding or potency of the second antibody ( Fig 1C, purple   60 text). This definition encompasses cases where the second antibody binds more tightly 61 (K
D ) in the presence of the first antibody, as 62 well as when the potency of the second antibody may increase (α 2,eff > α 2 ) or decrease 63 (α 2,eff < α 2 ). This also includes cases where two epitopes slightly overlap and partially 64 inhibit one another's binding, and the competitive binding model can be viewed as the 65 extreme limit K 67 While the synergistic model in Fig 1C has the merit of being highly general, an 68 important feature of the independent and competitive models ( Fig 1A,B ) is that they 69 predict all antibody combinations with few parameters. In both of these latter models, 70 once the K (j) D and α j of 10 antibodies are known (which requires 2 · 10 experiments) 71 and their epitopes are mapped ( 10·9 2 additional experiments), the potency of all 72 2 10 = 1024 possible mixtures of these antibodies can be predicted without recourse to 73 fitting. In contrast, because the synergistic model allows arbitrary interactions between 74 each combination of antibodies, the behavior of a mixture exhibiting synergy cannot be 75 predicted without actually making a measurement on that combination to quantify the 76 synergy.
77
For these reasons, in this work we focus on the two cases of independent or 78 competitive binding and show how we can combine both models to transform our 79 molecular understanding of each monoclonal antibody's action into a prediction of the 80 efficacy of an antibody mixture. Deviations from our predictions provide a rigorous way 81 to measure antibody synergy by computing
α2 .
82
To mathematize the independent and competitive binding models, we enumerate the 83 possible binding states and compute their relative Boltzmann weights. The fractional 84 activity of each state equals the product of its relative probability and relative activity 85 divided by the sum of all relative probabilities for normalization (see S1 Text Section A). 86 When two antibodies bind independently as in Fig 1A, this factors into the form 87 Fractional Activity (distinct epitopes) =
If these two antibodies compete for the same epitope as in Fig 1B, the activity becomes 88
Fractional Activity (overlapping epitopes) =
These equations are readily extended to mixtures with three or more antibodies (see S1 89 Text Section A). where ten monoclonal antibodies were individually characterized and then the activity 95 of all 165 possible 2-Ab and 3-Ab mixtures was measured [6] . We first use each 96 monoclonal antibody's response to infer its dissociation constant K D and potency α. 97 We then utilize surface plasmon resonance (SPR) measurements to determine which 98 pairs of antibodies bind independently and which compete for the same epitope. These 99 data enable us to use the above framework and predict EGFR activity in the presence 100 of any mixture.
101
EGFR is a transmembrane protein that activates in the presence of epidermal growth factors. Upon ligand binding, the receptor's intracellular tyrosine kinase domain 103 autophosphorylates which leads to downstream signaling cascades central to cell 104 migration and proliferation. Overexpression of EGFR has been linked to a number of 105 cancers, and decreasing EGFR activity in such tumors by sterically occluding ligand 106 binding has reduced the rate of cancer proliferation [6] . 107 Koefoed et al. investigated how a panel of ten monoclonal antibodies inhibit EGFR 108 activity in the human cell line A431NS [6] . They then measured how 1:1 mixtures of 109 two antibodies or 1:1:1 mixtures of three antibodies affect EGFR activity. All 110 measurement were carried out at a total concentration of 2 µg mL , implying that each given the individual activities of antibody #1 (0.65) and #2 (0.69), the predicted 165 activity of their combination (at the concentration of 1 µg mL for each antibody dictated by 166 the experiments) would be 0.45 if they bind to distinct epitopes and 0.67 if they bind to 167 overlapping epitopes. Since the measured activity of this mixture was 0.65, it suggests 168 the latter option. We note that such analysis will work best for potent antibodies 169 (whose individual activity is far from 1), since only in this regime will the predictions of 170 the distinct versus overlapping models be significantly different. Therefore, the activity 171 measurements of each individual antibody would optimally be carried out at saturating 172 concentrations (where Eq (1) is as far from 1 as possible).
173
Proceeding to the other antibodies, we characterize each pair according to whichever 174 model prediction lies closer to the experimental measurement. To account for 175 experimental error, we left an antibody pair uncategorized if the two model predictions 176 were too close to one another (within 4σ = 0.16 where σ is the SEM of the 177 measurements) or if the experimental measurement was close (within 1σ) to the average 178 of the two model predictions (see S1 Text Section B). individual activities close to 1, making them difficult to characterize).
185
Using these classifications, we defined unique EGFR epitopes by grouping together 186 any antibodies that bind to overlapping epitopes. In this way, we split the ten 187 antibodies into four distinct groups (antibodies #1-3, #4-5, #6, and #7-10 indicated by 188 the dashed gray rectangles in Fig 3A) , enabling us to distinguish which antibodies bind 189 independently or competitively and hence predict the activity of the 2-Ab and 3-Ab 190 mixtures. Note that it is not the pairwise classification between two antibodies that 191 determines whether we apply the distinct or competitive models, but rather these four 192 groupings of antibody epitopes. For example, although antibodies #7 and #8 are 193 uncategorized through their 2-Ab mixture, they fall within a single epitope group and 194 hence are considered to bind competitively. Similarly, antibody #1 and #4 are modeled 195 as binding independently because they belong to two distinct epitope groups. Antibody 196 #6 is considered to be in its own epitope group since it did not overlap with any other 197 antibody.
198 Surprisingly, the results shown in Fig 3B have a coefficient of determination 199 R 2 = 0.90 that is on par with the results obtained using the SPR measurements 200 ( Fig 2B) . Since the inferred epitope map relied on the 2-Ab activity data, we compared 201 the predicted activity of the 3-Ab mixtures using the epitopes inferred through SPR 202 with those inferred through the activity data and showed that they are nearly identical 203 (R 2 = 0.997, see S1 Text Section A). This suggests that there is no loss in the predictive 204 power of the model when an epitope mapping is inferred through activity measurements. 205 In summary, whether antibodies bind independently or competitively can be 90) as a model that relies on epitope groupings given by SPR measurements (Fig 2B) .
Multidomain antibodies boost breadth and potency via avidity 215
While the previous sections analyzed combinations of whole, unmodified antibodies, we 216 now extend our framework to connect with the rising tide of engineering efforts that 217 genetically fuse different antibody components to construct multi-domain antibodies [8] . 218 Specifically, we focus our attention on recent work by Laursen et al. who isolated 219 single-domain antibodies from llamas immunized with H2 or H7 influenza 220 hemagglutinin (HA) [7] . The four single-domain antibodies isolated in this manner 221 included one antibody that preferentially binds influenza A group 1 strains (Ab A1 ),
222
another that binds influenza A group 2 strains (Ab A2 ), and two antibodies that bind to 223 influenza B strains (Ab quantities may or may not be proportional [9] [10] [11] , and hence we replace dissociation 240 constants with IC 50 s in our model (see S1 Text Section C). (5)). (D) Theoretical predictions of the potency of all multidomain antibodies versus their measured values. The red points denote two outlier influenza strains discussed in the text that are not neutralized by Ab A1 or Ab A2 individually but are highly neutralized by their combination.
HA [7] . The linker connecting the two antibody domains facilitates such crosslinking, 244 since when one domain is bound the other domain is confined to a smaller volume 245 around its potential binding sites. This effect can be quantified by stating that the 246 second domain has an effective concentration c eff (Fig 4C, purple) , making the relative 247 probability of the doubly bound state c IC50,A1 c eff IC50,A2 . Therefore, the fraction of virus 248 neutralized by two tethered antibody domains is given by
.
(4)
Note that this equation assumes that influenza virus is fully neutralized at saturating 250 concentrations of antibody (α = 0 in Eq (1), with Fraction Neutralized analogous to 251 1 − Fractional Activity).
252
The IC 50 of the tethered construct is defined as the concentration c at which half of 253
October 16, 2019 9/15 the virus is neutralized, which can be solved to yield 254 IC 50,A1-A2 = IC 50,A1 IC 50,A2 c eff + IC 50,A1 + IC 50,A2 ,
with an analogous expression holding for the Ab we can infer the value of the single parameter c eff = 1400 nM (see S1 Text Section C).
257
This result is both physically meaningful and biologically actionable, as it enables us to 258 predict the IC 50 of the tethered multidomain antibodies against the entire panel of 259 influenza strains. Fig 5A,B compares The two tethered antibodies display unique trends that arise from their 263 compositions. Since the two domains in Ab A1 -Ab A2 bind nearly complementary strains, 264 the tethered construct will increase breadth (since this multidomain antibodies can now 265 bind to both group 1 and group 2 strains) but will only marginally improve potency.
266
Mathematically, if Ab A1 binds tightly to an influenza A group 1 strain while Ab A2 IC 50 = 17 nM, respectively, far more potent than the 300 nM lower limit predicted for 283 both viruses (red circles in Fig 4D and red lines in Fig 5A) . Interestingly, Laursen et 284 al. found that mixing the individual, untethered antibodies Ab A1 and Ab A2 also 285 resulted in shockingly poor neutralization (IC 50 ≥ 1000 nM), suggesting that the tether 286 is responsible for the increase in potency [7] . From the vantage of our quantitative 287 model, this outlier cries out for further investigation. Fig 5C) .
297
A second construct containing all four antibody domains attached two copies of 298 Ab A1 -Ab A2 -Ab Ab A2 Ab A1 Ab B Ab (1) Ab B Ab (2) Ab A2 Ab A1 Ab B Ab (1) Ab B Ab (2) (2) Ab B Ab (1) Ab B Ab (2) Ab (1) -Ab ( B , suggesting that there was no noticeable avidity 303 and that the increase in neutralization only arose from having twice as many antibody 304 domains. As above, this intriguing result presents an opportunity to both quantitatively 305 check experimental results and to advocate for future studies in potentially highly promising directions. In this particular instance, it suggests that the IgG backbone used 307 did not permit simultaneous binding of both arms. If a different multivalent scaffold 308 (perhaps with greater flexibility or with longer linkers) enabled bivalent binding of both 309 arms, it could potentially increase the neutralization of this construct by 100-fold as 310 seen in the influenza B constructs.
311
Discussion
312
In this work, we developed a statistical mechanical model that predicts the collective 313 efficacy of an antibody mixture whose constituents are assumed to bind to a single site 314 on a receptor. Each antibody is first individually characterized by its ability to bind the 315 receptor (through its dissociation constant K D ) and inhibit activity (via its potency α) 316 as per Eq (1). Importantly, this implies that the activity of each monoclonal antibody 317 must be measured at a minimum of two concentrations in order to infer both 318 parameters, and additional measurements would further refine these parameter values 319 and the corresponding model predictions.
320
After each antibody is individually characterized, the activity of a combination of 321 antibodies will depend upon whether they bind independently to distinct epitopes or 322 compete for overlapping epitopes. Theoretical models often assume for simplicity that 323 all antibodies bind independently, and in the contexts where this constraint can be 324 experimentally imposed such models can accurately predict the effectiveness of antibody 325 mixtures [12] . Yet when the antibody epitopes are unknown or when a large number of 326 antibodies are combined, it is likely that some subset of antibodies will compete with 327 each other while others will bind independently, which will give rise to a markedly 328 different response. Our model generalized these previous results to account for antibody 329 mixtures where arbitrary subsets can bind independently or competitively (Eqs (2) and 330 (3), S1 Text Section A). 331 We showed that in the context of the EGFR receptor, where every pairwise 332 interaction was measured using surface plasmon resonance, our model is better able to 333 predict the efficacy of all 2-Ab and 3-Ab mixtures than a model that assumes all 334 antibodies bind independently or competitively (Fig 2) . This suggest that mixtures of 335 antibodies do not exhibit large synergistic effects. More generally, similar models in the 336 contexts of anti-cancer drug cocktails and anti-HIV antibody mixtures also found that 337 the majority of cases that were described as synergistic could instead be characterized 338 by an independent binding model [12, 13] . This raises the possibility that synergy is 339 more the exception then the norm, and hence that simple models can computationally 340 explore the full design space of antibody combinations.
341
While it is often straightforward to measure the efficacy of n individual antibodies, it 342 is more challenging to quantify all n(n+1) 2 pairwise interactions and determine which 343 antibodies bind independently and which compete for an overlapping epitope. We 344 demonstrated that after each antibody is individually characterized, our model can be 345 applied in reverse by using the activity of 2-Ab mixtures to classify whether antibodies 346 compete or bind independently (Fig 3) . Surprisingly, while the resulting categorizations 347 were much sparser than the direct SPR measurements, the classifications produced by 348 this method predicted the efficacy of antibody combinations with an R 2 = 0.90, 349 comparable to the predictions made using the complete SPR results ( Fig 2B) . This IC 50 s for the individual antibody domains in Panels A and B). For such constructs, the 358 composition of the linker can heavily influence the ability to multivalently bind and 359 neutralize a virus [11, 14] , although Laursen et al. surprisingly found little variation 360 when they modified the length of their amino acid linker (see Table S11 in Ref [7] ).
361
Another curious feature of their system was that placing their linear 4-domain antibody 362 ( Fig 5C) on an IgG backbone ( Fig 5D) only resulted in a 2x decrease in IC 50 , suggesting 363 that the two "arms" of the IgG could not simultaneously bind. We would expect that a 364 different backbone that allows both arms to simultaneously bind would markedly 365 increase the neutralization potency of this construct. In this way, quantitatively 366 modeling these multidomain antibodies can guide experimental efforts to design more 367 potent constructs.
368
To close, we mention that two possible avenues of future work. First, although our 369 model classifies antibody epitopes as either distinct or overlapping, SPR measurements 370 indicate that there is a continuum of possible interactions. It would be fascinating to 371 translate this more nuanced level of interaction into more precise dissociation constants 372 when two antibodies are bound. Second, while our model focused on mixtures of 373 antibodies, it can be applied equally well to small molecule drugs where the number of 374 distinct combinations may be prohibitively large to measure experimentally but 375 straightforward to explore computationally.
376
Methods
377
The coefficient of determination used to quantify how well the theoretical predictions 378 matched the experimental measurements ( Fig 2B-D, Fig 3B, Fig 4D) where y measured and y predicted represent a vector of the measured and predicted 381 activities for the n mixtures analyzed. In Fig 4D, we computed the R 2 of log 10 (activity) 382 to prevent the largest activities from dominating the result (since the IC 50 values span 383 multiple decades).
384
Data from the EGFR antibody mixtures was obtained by digitizing Ref [6] Fig S1   385 using WebPlotDigitizer [15] . Data for the influenza multidomain antibodies was 386 obtained from the authors of Ref [7] .
387
The EGFR antibody epitopes experimentally characterized through SPR (Fig 3A,   388 bottom-left) were categorized as overlapping if the average of the two antibody 389 measurements (with preincubation by either antibody) were > 50 and as distinct if the 390 average was < 50.
391
The original nomenclature for the antibodies used in Koefoed et al. and Laursen et 392 al. are given in S1 Text Table S1 . 393 Author contributions 394 T.E. and J.D.B. both participated in the conceptualization, investigation, and writing of 395 this work.
